Expert Review of Clinical Pharmacology最新文献

筛选
英文 中文
The future of pharmacology education: The Veterinary Educators in Pharmacology Special Interest Group (VEPSIG). 药理学教育的未来:兽医药理学教育工作者特别兴趣小组(VEPSIG)。
IF 4.4 3区 医学
Expert Review of Clinical Pharmacology Pub Date : 2024-03-01 Epub Date: 2024-02-07 DOI: 10.1080/17512433.2024.2315309
Martin Hawes, Arno Werners
{"title":"The future of pharmacology education: The Veterinary Educators in Pharmacology Special Interest Group (VEPSIG).","authors":"Martin Hawes, Arno Werners","doi":"10.1080/17512433.2024.2315309","DOIUrl":"10.1080/17512433.2024.2315309","url":null,"abstract":"","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"303-304"},"PeriodicalIF":4.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139680970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of different levothyroxine administration regimens on thyroid hormone levels: a systematic review, pairwise, and network meta-analysis. 甲状腺功能减退症中的左甲状腺素给药方案不同左甲状腺素给药方案对甲状腺激素水平的影响:系统综述、配对分析和网络荟萃分析。
IF 3.6 3区 医学
Expert Review of Clinical Pharmacology Pub Date : 2024-03-01 Epub Date: 2024-02-05 DOI: 10.1080/17512433.2024.2313616
Bianca Vendruscolo Bianchini, Patricia Romualdo de Jesus, Renato Gorga Bandeira de Mello, Patricia Klarmann Ziegelmann, Kristian Bellevue Filion, Tatiane da Silva Dal Pizzol
{"title":"The effect of different levothyroxine administration regimens on thyroid hormone levels: a systematic review, pairwise, and network meta-analysis.","authors":"Bianca Vendruscolo Bianchini, Patricia Romualdo de Jesus, Renato Gorga Bandeira de Mello, Patricia Klarmann Ziegelmann, Kristian Bellevue Filion, Tatiane da Silva Dal Pizzol","doi":"10.1080/17512433.2024.2313616","DOIUrl":"10.1080/17512433.2024.2313616","url":null,"abstract":"<p><strong>Introduction: </strong>This systematic review aimed to compare the effect of alternative levothyroxine administration regimens on thyroid hormone levels and patient-reported outcomes (PROs) among adults with hypothyroidism.</p><p><strong>Methods: </strong>We searched PubMed, Embase, CENTRAL, CINAHL, LILACS, SciELO, Scopus, Web of Science, OpenGrey, ProQuest, ClinicalTrials.gov, and ICTRP from inception to May/2023 for randomized controlled trials (RCTs). We assessed the risk of bias with Cochrane Risk of Bias 2.0 tool. We analyzed TSH levels by pairwise and network meta-analyses (NMA). The FT4 levels and PROs were qualitatively assessed.</p><p><strong>Results: </strong>We included 14 RCTs (906 participants) comparing different regimens, as bedtime vs. before breakfast. A total of 12 RCTs were at high risk of bias. Seven RCTs were included in the TSH meta-analysis, where the mean difference (MD) and 95% confidence interval (CI) were as follows: bedtime vs before breakfast (4 RCTs) 0.69 (-1.67-3.04), I<sup>2</sup> = 92%, very low certainty evidence; weekly dose vs before breakfast (2 RCTs) 1.68 (0.94-2.41), I<sup>2</sup> = 0%, low certainty evidence; and at breakfast vs before breakfast (1 RCT) 0.65 (-1.11-2.41), very low certainty evidence. The NMA showed no evidence of differences in TSH level with different regimens.</p><p><strong>Conclusion: </strong>The evidence is insufficient to determine the most effective levothyroxine administration regimen for hypothyroidism.</p><p><strong>Systematic review registration: </strong>PROSPERO - CRD42021279375.</p>","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"275-291"},"PeriodicalIF":3.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139641973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarker discovery in acetaminophen hepatotoxicity: leveraging single-cell transcriptomics and mechanistic insight 对乙酰氨基酚肝毒性的生物标志物发现:利用单细胞转录组学和机理洞察力
IF 4.4 3区 医学
Expert Review of Clinical Pharmacology Pub Date : 2024-01-13 DOI: 10.1080/17512433.2024.2306219
David S Umbaugh, Hartmut Jaeschke
{"title":"Biomarker discovery in acetaminophen hepatotoxicity: leveraging single-cell transcriptomics and mechanistic insight","authors":"David S Umbaugh, Hartmut Jaeschke","doi":"10.1080/17512433.2024.2306219","DOIUrl":"https://doi.org/10.1080/17512433.2024.2306219","url":null,"abstract":"Acetaminophen (APAP) overdose is the leading cause of drug-induced liver injury and can cause a rapid progression to acute liver failure (ALF). Therefore, the identification of prognostic biomarker...","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":"273 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139458529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations. 桔梗临床药理学的最新进展:用途、滥用潜力和未来考虑。
IF 4.4 3区 医学
Expert Review of Clinical Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-29 DOI: 10.1080/17512433.2024.2305798
Christopher R McCurdy, Abhisheak Sharma, Kirsten E Smith, Charles A Veltri, Stephanie T Weiss, Charles M White, Oliver Grundmann
{"title":"An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations.","authors":"Christopher R McCurdy, Abhisheak Sharma, Kirsten E Smith, Charles A Veltri, Stephanie T Weiss, Charles M White, Oliver Grundmann","doi":"10.1080/17512433.2024.2305798","DOIUrl":"10.1080/17512433.2024.2305798","url":null,"abstract":"<p><strong>Introduction: </strong>Kratom (<i>Mitragyna speciosa</i>) has generated substantial clinical and scientific interest as a complex natural product. Its predominant alkaloid mitragynine and several stereoisomers have been studied for activity in opioid, adrenergic, and serotonin receptors. While awaiting clinical trial results, the pre-clinical evidence suggests a range of potential therapeutic applications for kratom with careful consideration of potential adverse effects.</p><p><strong>Areas covered: </strong>The focus of this review is on the pharmacology, pharmacokinetics, and potential drug-drug interactions of kratom and its individual alkaloids. A discussion on the clinical pharmacology and toxicology of kratom is followed by a summary of user surveys and the evolving concepts of tolerance, dependence, and withdrawal associated with kratom use disorder.</p><p><strong>Expert opinion: </strong>With the increasing use of kratom in clinical practice, clinicians should be aware of the potential benefits and adverse effects associated with kratom. While many patients may benefit from kratom use with few or no reported adverse effects, escalating dose and increased use frequency raise the risk for toxic events in the setting of polysubstance use or development of a use disorder.</p>","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"131-142"},"PeriodicalIF":4.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10846393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study. 布景和环境可预测精神病理学、幸福感和迷幻体验的意义:一项相关研究。
IF 4.4 3区 医学
Expert Review of Clinical Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-29 DOI: 10.1080/17512433.2023.2295997
Lucas F Borkel, Jaime Rojas-Hernández, Luis Alberto Henríquez-Hernández, Ángelo Santana Del Pino, Domingo J Quintana-Hernández
{"title":"Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study.","authors":"Lucas F Borkel, Jaime Rojas-Hernández, Luis Alberto Henríquez-Hernández, Ángelo Santana Del Pino, Domingo J Quintana-Hernández","doi":"10.1080/17512433.2023.2295997","DOIUrl":"10.1080/17512433.2023.2295997","url":null,"abstract":"<p><strong>Background: </strong>In psychedelic therapy, the importance of set and setting is a fundamental but under-researched assumption. The aim of this study is to correlate variables of set (psychedelic use motivation) and setting (psychedelic use location and type of companion) with psychopathology, wellbeing and personality variables.</p><p><strong>Research design and methods: </strong>A sample of 1022 participants of the Spanish-speaking population was collected through an online survey. A novel instrument, the Psychedelic Use Scale (PUS), was developed to measure substance use variables of LSD, mescaline, psilocybin, DMT, 5-Meo-DMT, ketamine, <i>Salvia divinorum</i>, ibogaine and MDMA. Various personality, well-being and psychopathology instruments were implemented to measure outcome variables.</p><p><strong>Results: </strong>Growth motivations, natural settings and presence of significant others predicted less psychopathology, greater wellbeing and meaningfulness of psychedelic experiences, whereas problematic motivations predicted greater psychopathology, lower wellbeing and did not predict meaningfulness of psychedelic experiences.</p><p><strong>Conclusions: </strong>Based on these results, we suggest experimental hypotheses for future clinical trials and longitudinal studies with potential clinical implications.</p>","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"165-176"},"PeriodicalIF":4.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138801873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population pharmacokinetics of antibacterial agents in the older population: a literature review. 老年人口中抗菌药物的群体药代动力学:文献综述。
IF 4.4 3区 医学
Expert Review of Clinical Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-23 DOI: 10.1080/17512433.2023.2295009
Hui-Xin Liu, Bo-Hao Tang, John van den Anker, Guo-Xiang Hao, Wei Zhao, Yi Zheng
{"title":"Population pharmacokinetics of antibacterial agents in the older population: a literature review.","authors":"Hui-Xin Liu, Bo-Hao Tang, John van den Anker, Guo-Xiang Hao, Wei Zhao, Yi Zheng","doi":"10.1080/17512433.2023.2295009","DOIUrl":"10.1080/17512433.2023.2295009","url":null,"abstract":"<p><strong>Introduction: </strong>Older individuals face an elevated risk of developing bacterial infections. The optimal use of antibacterial agents in this population is challenging because of age-related physiological alterations, changes in pharmacokinetics (PK) and pharmacodynamics (PD), and the presence of multiple underlying diseases. Therefore, population pharmacokinetics (PPK) studies are of great importance for optimizing individual treatments and prompt identification of potential risk factors.</p><p><strong>Area covered: </strong>Our search involved keywords such as 'elderly,' 'old people,' and 'geriatric,' combined with 'population pharmacokinetics' and 'antibacterial agents.' This comprehensive search yielded 11 categories encompassing 28 antibacterial drugs, including vancomycin, ceftriaxone, meropenem, and linezolid. Out of 127 studies identified, 26 (20.5%) were associated with vancomycin, 14 (11%) with meropenem, and 14 (11%) with piperacillin. Other antibacterial agents were administered less frequently.</p><p><strong>Expert opinion: </strong>PPK studies are invaluable for elucidating the characteristics and relevant factors affecting the PK of antibacterial agents in the older population. Further research is warranted to develop and validate PPK models for antibacterial agents in this vulnerable population.</p>","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"19-31"},"PeriodicalIF":4.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence and machine learning in clinical pharmacological research. 人工智能和机器学习在临床药理研究中的应用。
IF 4.4 3区 医学
Expert Review of Clinical Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-23 DOI: 10.1080/17512433.2023.2294005
Benjamin Mayer, Dario Kringel, Jörn Lötsch
{"title":"Artificial intelligence and machine learning in clinical pharmacological research.","authors":"Benjamin Mayer, Dario Kringel, Jörn Lötsch","doi":"10.1080/17512433.2023.2294005","DOIUrl":"10.1080/17512433.2023.2294005","url":null,"abstract":"<p><strong>Background: </strong>Clinical pharmacology research has always involved computational analysis. With the abundance of drug-related data available, the integration of artificial intelligence (AI) and machine learning (ML) methods has emerged as a promising way to enhance clinical pharmacology research.</p><p><strong>Methods: </strong>Based on an accepted definition of clinical pharmacology as a field of research dealing with all aspects of drug-human interactions, the analysis included publications from institutes specializing in clinical pharmacology. Research topics and the most used machine learning methods in clinical pharmacology were retrieved from the PubMed database and summarized.</p><p><strong>Results: </strong>ML was identified in 674 publications attributed to clinical pharmacology research, with a significant increase in publication activity over the last decade. Notable research topics addressed by ML/AI included Covid-19-related clinical pharmacology research, clinical neuropharmacology, drug safety and risk assessment, clinical pharmacology related to cancer research, and antimicrobial and antiviral research unrelated to Covid-19. In terms of ML methods, neural networks, random forests, and support vector machines were frequently mentioned in the abstracts of the retrieved papers.</p><p><strong>Conclusions: </strong>ML, and AI in general, is increasingly being used in various research areas within clinical pharmacology. This report presents specific examples of applications and highlights the most used ML methods.</p>","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"79-91"},"PeriodicalIF":4.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139073808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical trial design for assessing hypertension medications: are critical circadian chronopharmacological principles being taking into account? 评估高血压药物的临床试验设计:是否考虑了重要的昼夜时相药理学原则?
IF 4.4 3区 医学
Expert Review of Clinical Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-29 DOI: 10.1080/17512433.2024.2304015
Ramón C Hermida, Michael H Smolensky, Artemio Mojón, José R Fernández
{"title":"Clinical trial design for assessing hypertension medications: are critical circadian chronopharmacological principles being taking into account?","authors":"Ramón C Hermida, Michael H Smolensky, Artemio Mojón, José R Fernández","doi":"10.1080/17512433.2024.2304015","DOIUrl":"10.1080/17512433.2024.2304015","url":null,"abstract":"<p><strong>Introduction: </strong>Clinical hypertension trials typically rely on homeostatic principles, including single time-of-day office blood pressure (BP) measurements (OBPM), rather than circadian chronopharmacological principles, including ambulatory monitoring (ABPM) done around-the-clock to derive the asleep systolic BP (SBP) mean and sleep-time relative SBP decline - jointly the strongest prognosticators of cardiovascular disease (CVD) risk and true definition of hypertension - to qualify participants and assess outcomes.</p><p><strong>Areas covered: </strong>Eight chronopharmacological elements are indispensable for design and conduct of hypertension medication trials, mainly those on ingestion-time differences in effects, and also a means of rating quality of investigations. Accordingly, we highlight the findings and shortcomings of: (i) 155 such ingestion-time trials, 83.9% finding at-bedtime/evening treatment more beneficial than conventional upon-awakening/morning treatment; (ii) HOPE and ONTARGET CVD outcomes investigations assessing in the former add-on ramipril at-bedtime and in the latter telmisartan, ramipril, or both in combination in the morning; and (iii) pragmatic TIME CVD outcomes trial.</p><p><strong>Expert opinion: </strong>Failure to incorporate chronopharmacological principals - including ABPM to derive asleep SBP and SBP dipping to qualify subjects as hypertensive and assess CVD risk - results in deficient study design, dubious findings, and unnecessary medical controversy at the expense of advances in patient care.</p>","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"119-130"},"PeriodicalIF":4.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The future of pharmacology education: a global outlook. 药理学教育的未来:全球展望。
IF 4.4 3区 医学
Expert Review of Clinical Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-29 DOI: 10.1080/17512433.2024.2302602
Clare Guilding, Roisin Kelly-Laubscher, Paul White
{"title":"The future of pharmacology education: a global outlook.","authors":"Clare Guilding, Roisin Kelly-Laubscher, Paul White","doi":"10.1080/17512433.2024.2302602","DOIUrl":"10.1080/17512433.2024.2302602","url":null,"abstract":"","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"115-118"},"PeriodicalIF":4.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence-based model for dose prediction of sertraline in adolescents: a real-world study. 基于人工智能的青少年舍曲林剂量预测模型:一项真实世界研究。
IF 4.4 3区 医学
Expert Review of Clinical Pharmacology Pub Date : 2024-01-01 Epub Date: 2024-01-29 DOI: 10.1080/17512433.2024.2304009
Ran Fu, Ze Yu, Chunhua Zhou, Jinyuan Zhang, Fei Gao, Donghan Wang, Xin Hao, Xiaolu Pang, Jing Yu
{"title":"Artificial intelligence-based model for dose prediction of sertraline in adolescents: a real-world study.","authors":"Ran Fu, Ze Yu, Chunhua Zhou, Jinyuan Zhang, Fei Gao, Donghan Wang, Xin Hao, Xiaolu Pang, Jing Yu","doi":"10.1080/17512433.2024.2304009","DOIUrl":"10.1080/17512433.2024.2304009","url":null,"abstract":"<p><strong>Background: </strong>Variability exists in sertraline pharmacokinetic parameters in individuals, especially obvious in adolescents. We aimed to establish an individualized dosing model of sertraline for adolescents with depression based on artificial intelligence (AI) techniques.</p><p><strong>Methods: </strong>Data were collected from 258 adolescent patients treated at the First Hospital of Hebei Medical University between December 2019 to July 2022. Nine different algorithms were used for modeling to compare the prediction abilities on sertraline daily dose, including XGBoost, LGBM, CatBoost, GBDT, SVM, ANN, TabNet, KNN, and DT. Performance of four dose subgroups (50 mg, 100 mg, 150 mg, and 200 mg) were analyzed.</p><p><strong>Results: </strong>CatBoost was chosen to establish the individualized medication model with the best performance. Six important variables were found to be correlated with sertraline dose, including plasma concentration, PLT, MPV, GL, A/G, and LDH. The ROC curve and confusion matrix exhibited the good prediction performance of CatBoost model in four dose subgroups (the AUC of 50 mg, 100 mg, 150 mg, and 200 mg were 0.93, 0.81, 0.93, and 0.93, respectively).</p><p><strong>Conclusion: </strong>The AI-based dose prediction model of sertraline in adolescents with depression had a good prediction ability, which provides guidance for clinicians to propose the optimal medication regimen.</p>","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"177-187"},"PeriodicalIF":4.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139402453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信